Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAF156 plus lumefantrine SDF in pediatric uncomplicated Plasmodium falciparum malaria
PACTR202012535210091Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, single-arm trial of ganaplacide and lumefantrine in Malaria, sponsored by Novartis. Primary endpoint: PCR-corrected adequate clinical and parasitological response at Day 29. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
ganaplacidelumefantrine
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR202012535210091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202012535210091.